Gastric Cancer

Docetaxel plus cisplatin used as second-line combined therapy in gastric cancer

Published in Blood Weekly, September 29th, 2005

Docetaxel plus cisplatin was used as a second-line combined therapy in patients with advanced gastric carcinoma.

"We conducted a pilot phase II study to evaluate the efficacy and safety of docetaxel and cisplatin as a combination second-line therapy for advanced gastric cancer. Between 2000 and 2003, 30 patients were enrolled into this study. Chemotherapy consisted of 60 mg/m² of docetaxel followed by 60 mg/m² of cisplatin," scientists in Japan reported.

"This regimen was repeated at least three times at 3-week intervals. The overall response rate was 26.7%. The median time to disease progression was 4.5 months. The median...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2005-09-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry